## FY 2020 GPRA/GPRAMA IDCS National Results

INDIAN HEALTH SERVICE (IHS) GPRA/GPRAMA PERFORMANCE RESULTS

## Introduction

Beginning with FY 2018, IHS clinical GPRA results are calculated from the Integrated Data Collection System (IDCS), a data mart within the National Data Warehouse (NDW) General Data Mart. Service unit/health program data is exported to the NDW by reporting sites for inclusion in GPRA results.
The measure logic is programmed centrally within the IDCS data mart and mimics the CRS measure logic, which is located here
Each clinical measure has two graphs:

- IHS national performance result and historical data
- IHS Area graphs comparing the current reporting year to the previous year for each of IHS's twelve Area Offices.
- FY 2020 National results include data from IHS, Tribal, and Urban Indian health programs (prior to FY 2018 urban results were posted separately).
- FY 2019 National results include data from IHS, Tribal, and Urban Indian health programs (prior to FY 2018 urban results were posted separately).


## Area Abbreviations

| Abbreviation | Area |
| :---: | :--- |
| ALA | Alaska |
| ALB | Albuquerque |
| BEM | Bemidji |
| BIL | Billings |
| CAL | California |
| GPA | Great Plains |
| NAS | Nashville |
| NAV | Navajo |
| OKL | Oklahoma |
| PHX | Phoenix |
| POR | Portland |
| TUC | Tucson |

## Acronym Definitions

| Acronym | Definition |
| :--- | :--- |
| NPIRS | National Patient Information Reporting System |
| NDW | National Data Warehouse |
| IDCS | Integrated Data Collection System |
| AI/AN | American Indian/Alaska Native |
| A1c | Hemoglobin A1c |
| BMI | Body Mass Index |
| BP | Blood Pressure |
| CHD | Coronary Heart Disease |
| CVD | Cardiovascular Disease |
| DV/IPV | Domestic Violence/Intimate Partner Violence |
| HP | Healthy People |
| IHD | Ischemic Heart Disease |
| LDL | Low Density Lipoprotein |
| MH | Million Hearts |
| HIV | Human Immunodeficiency Virus |
| SBIRT | Screening, Brief Intervention, \& Referral to Treatment |

## GPRA 2020 Results Summary

Of the 26 measures that IHS/Tribal/Urban programs reported in FY 2020:

- 6 measures improved over FY 2019 results*
- 2 measures had no change from FY 2019 results
- 18 measures decreased in performance from FY 2019 results
- 3 measures met or exceeded FY 2020 targets
- 23 measures did not meet FY 2020 targets
- The DV/IPV GPRAMA measure did not meet the 2020 target
*FY 2020 results were expected to be significantly lower in FY 2020 due to the COVID pandemic and its impact on the healthcare system


## FY 2020 IHS/Tribal/Urban Results Summary

In FY 2020, 6 measures improved over FY 2019 performance

| Measure | FY 2019 Q4 | FY 2020 Q4 | \% Improvement |
| :--- | :---: | :---: | :---: |
| Diabetes: Statin Therapy | $47.4 \%$ | $50.2 \%$ | $2.8 \%$ |
| HIV Screen Ever | $30.9 \%$ | $33.7 \%$ | $2.8 \%$ |
| CVD Statin Therapy | $32.2 \%$ | $34.5 \%$ | $2.3 \%$ |
| Diabetes: Poor Glycemic Control | $17.4 \%$ | $16.4 \%$ | $1.0 \%$ |
| Influenza Vaccination 18+ | $23.6 \%$ | $24.3 \%$ | $0.7 \%$ |
| Breastfeeding Rates | $38.7 \%$ | $39.3 \%$ | $0.6 \%$ |

## FY 2020 IHS/Tribal/Urban Results Summary

In FY 2020, 2 measures had no change in performance from FY 2019

| Measure | FY 2019 Q4 | FY 2020 Q4 | \% Change |
| :--- | :---: | :---: | :---: |
| Influenza Vaccination 6mo - 17yrs | $25.7 \%$ | $25.7 \%$ | $0.0 \%$ |
| SBIRT | $14.9 \%$ | $14.9 \%$ | $0.0 \%$ |

## FY 2020 IHS/Tribal/Urban Results Summary

In FY 2020, 18 measures decreased in performance from FY 2019

| Measure | FY 2019 Q4 | FY 2020 Q4 | \% Decrease |
| :--- | :--- | :--- | :--- |
| Adult Immunizations | $53.3 \%$ | $39.1 \%$ | $14.2 \%$ |
| Diabetes: Retinopathy Exam | $49.7 \%$ | $37.4 \%$ | $12.3 \%$ |
| Topical Fluorides | $32.1 \%$ | $22.1 \%$ | $10.0 \%$ |
| Tobacco Cessation | $32.9 \%$ | $25.3 \%$ | $7.6 \%$ |
| Depression Screening 12-17yrs | $37.3 \%$ | $30.1 \%$ | $7.2 \%$ |
| Dental: General Access | $30.0 \%$ | $22.9 \%$ | $7.1 \%$ |
| Universal Alcohol Screening | $40.7 \%$ | $34.0 \%$ | $6.7 \%$ |
| IPV/DV Screening | $36.3 \%$ | $30.2 \%$ | $6.1 \%$ |
| Diabetes: Nephropathy Assessed | $44.0 \%$ | $38.8 \%$ | $5.2 \%$ |

## FY 2020 IHS/Tribal/Urban Results Summary

(continued from previous slide):
In FY 2020, 18 measures decreased in performance from FY 2019

| Measure | FY 2019 Q4 | FY 2020 Q4 | \% Decrease |
| :--- | :---: | :---: | :---: |
| Depression Screening 18+ | $42.6 \%$ | $37.4 \%$ | $5.2 \%$ |
| Mammography Screening | $42.0 \%$ | $36.9 \%$ | $5.1 \%$ |
| Dental: Sealants | $15.9 \%$ | $11.2 \%$ | $4.7 \%$ |
| Diabetes: Controlled BP | $57.2 \%$ | $52.7 \%$ | $4.5 \%$ |
| Controlling High BP (MH) | $41.5 \%$ | $37.9 \%$ | $3.6 \%$ |
| Colorectal Cancer Screening | $31.5 \%$ | $28.6 \%$ | $2.9 \%$ |
| Cervical (Pap) Screening | $37.1 \%$ | $35.3 \%$ | $1.8 \%$ |
| Childhood Immunizations | $41.4 \%$ | $39.9 \%$ | $1.5 \%$ |
| Childhood Weight Control | $22.7 \%$ | $23.3 \%$ | $0.6 \%$ |

## Diabetes: Poor Glycemic Control

AI/AN patients with diabetes who have had Poor A1c control ( $>9$ ) during the past year.


Diabetes: Poor Glycemic Control


## Diabetes: Blood Pressure Control

AI/AN patients with diabetes who have maintained BP control ( $<140 / 90$ ) during the past year.


## Diabetes: Blood Pressure Control (<140/90)



Diabetes: Statin Therapy to Prevent Cardiovascular Disease Risk
AI/AN patients with diabetes who are statin therapy users or receive a prescription for statin therapy during the report period.


## Diabetes: Statin Therapy to Prevent CVD Risk



Diabetes: Nephropathy Assessment
AI/AN patients with diabetes who have been assessed for nephropathy within the past year.


## Diabetes: Nephropathy Assessment



Diabetes: Retinopathy
AI/AN patients with diabetes who have been assessed for retinopathy within the past year.


## Diabetes: Retinopathy



Dental: General Access
AI/AN patients who have received dental services within the past year.


## Dental: General Access



## Dental: Sealants

AI/AN children with intact dental sealants.


## Dental: Sealants



## Dental: Topical Fluorides

AI/AN children with at least one topical fluoride treatment within the past year.


## Dental: Topical Fluorides



Immunizations: Influenza 6mo-17yrs
AI/AN patients (ages 6 months to 17 years) who have received the influenza vaccine within the past year.


## Immunizations: Influenza 6mo-17yr



## Immunizations: Influenza 18+

AI/AN patients (ages $18+$ ) who have received the influenza vaccine within the past year.


## Immunizations: Influenza 18+



## Immunizations: Adult Immunizations

AI/AN patients (age 19+) who have received all age-appropriate immunization combinations.


Adult Immunizations


## Immunizations: Childhood (19-35 months)

AI/AN patients (age 19-35 months) who have received the combined childhood vaccination series (4:3:1:3*:3:1:4).


## Immunizations: Childhood (19-35 months)



## Cancer Screening: Cervical (Pap Screen)

AI/AN women age 24-64 who have received a Pap screen
within the previous three years, or age 30-64 years with a Pap screen in the past three years or a Pap Screen and an HPV DNA in the past five years.


## Cancer Screening: Cervical (Pap Screen)



## Cancer Screening: Breast (Mammography)

AI/AN women (age 52-74) who have received mammography screening within the previous two years.

*Prior to FY 2019, measure tracked women ages 52-64 years

## Cancer Screening: Breast (Mammography)



## Cancer Screening: Colorectal

AI/AN patients ages 50-75 who have received appropriate Colorectal Cancer Screening.


## Cancer Screening: Colorectal



## Tobacco Cessation

AI/AN tobacco-using patients who have received tobacco cessation intervention within the past year or quit their tobacco use within the past year.


## Tobacco Cessation



## Universal Alcohol Screening

AI/AN patients ages 9-75 who have been screened for alcohol use within the past year.


## Universal Alcohol Screening



## Screening, Brief Intervention, Referral to Treatment (SBIRT)

AI/AN patients ages 9-75 who screened positive for alcohol use and were provided a brief intervention or brief negotiated interview within seven days of the positive
screen


SBIRT


## Domestic Violence/Intimate Partner Violence Screening:

AI/AN women (age 14-46) who were screened for domestic violence /intimate partner violence within the past year.


## DV/IPV Screening



Depression Screening 12-17
AI/AN patients ages 12-17 who have been screened for depression or diagnosed with a mood disorder within the past year.


## Depression Screening 12-17 years



## Depression Screening $18+$

AI/AN patients ages 18 and older who have been screened for depression or diagnosed with a mood disorder within the past year.


Depression Screening 18+


Childhood Weight Control (CWC)
AI/AN children ages $2-5$ years with a BMI at or above 95th percentile.


## Childhood Weight Control



## HIV Screening Ever

AI/AN patients who have ever received screening for HIV.


## HIV Screening Ever



## CVD Statin Therapy

Patients age 40 to 75 with diabetes, or age 21 and older with documented CVD or an LDL greater than or equal to 190 who are statin therapy users or receive a prescription for statin therapy


## CVD Statin Therapy



## Controlling High Blood Pressure (MH)

AI/AN patients with diagnosed hypertension who have achieved blood pressure control (<140/90).


## Controlling High Blood Pressure (MH)



## Breastfeeding Rates

AI/AN patients who, at the age of two months, were either exclusively or mostly breastfed.


## Breastfeeding Rates



| DIABETES | FY 2019 Target | FY 2019 Final | FY 2020 Target | FY 2020 Final | FY 2020 Final Results |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Poor Glycemic Controla | Baseline | 17.4\% | 17.4\% | 16.4\% | Met |
| Controlled BP <140/90 | 52.3\% | 57.2\% | 60.5\% | 52.7\% | Not Met |
| Statin Therapy | 37.5\% | 47.4\% | 51.6\% | 50.2\% | Not Met |
| Nephropathy Assessed | 34.0\% | 44.0\% | 48.1\% | 38.8\% | Not Met |
| Retinopathy Exam | 49.7\% | 49.7\% | 53.5\% | 37.4\% | Not Met |
| DENTAL |  |  |  |  |  |
| Dental: General Access | 27.2\% | 30.0\% | 29.7\% | 22.9\% | Not Met |
| Sealants | 16.0\% | 15.9\% | 17.2\% | 11.2\% | Not Met |
| Topical Fluoride | 30.0\% | 32.1\% | 34.5\% | 22.1\% | Not Met |
| IMMUNIZATIONS |  |  |  |  |  |
| Influenza Vaccination 6mo - 17yrs | 20.6\% | 25.7\% | 26.1\% | 25.7\% | Not Met |
| Influenza Vaccination 18+ | 18.8\% | 23.6\% | 25.4\% | 24.3\% | Not Met |
| Adult Immunizations | 54.9\% | 53.3\% | 59.7\% | 39.1\% | Not Met |
| Childhood IZ | 45.6\% | 41.4\% | 45.9\% | 39.9\% | Not Met |
| PREVENTION |  |  |  |  |  |
| (Cervical) Pap Screening | 35.9\% | 37.1\% | 39.2\% | 35.3\% | Not Met |
| Mammography Screening ${ }^{\text {b }}$ | Baseline | 42.0\% | 42.0\% | 36.9\% | Not Met |
| Colorectal Cancer Screening | 32.6\% | 31.5\% | 34.7\% | 28.6\% | Not Met |
| Tobacco Cessation | 27.5\% | 32.9\% | 31.4\% | 25.3\% | Not Met |
| Universal Alcohol Screening | 37.0\% | 40.7\% | 42.4\% | 34.0\% | Not Met |
| SBIRT | 8.9\% | 14.9\% | 12.2\% | 14.9\% | Met |
| IPV/DV Screening | 41.6\% | 36.3\% | 41.5\% | 30.2\% | Not Met |
| Depression Screening 12-17 years | 27.6\% | 37.3\% | 38.0\% | 30.1\% | Not Met |
| Depression Screening 18+ | 42.2\% | 42.6\% | 45.7\% | 37.4\% | Not Met |
| Childhood Weight Control | 22.6\% | 22.7\% | 22.6\% | 23.3\% | Not Met |
| Controlling High Blood Pressure (MH) | 42.3\% | 41.5\% | 52.6\% | 37.9\% | Not Met |
| CVD Statin Therapy | 26.6\% | 32.2\% | 35.7\% | 34.5\% | Not Met |
| HIV Screen Ever | 17.3\% | 30.9\% | 28.4\% | 33.7\% | Met |
| Breastfeeding Rates | 39.0\% | 38.7\% | 43.6\% | 39.3\% | Not Met |

aNew measure as of FY 2019.
Measures Met: 3
bogic change in FY 2019.
Measures Not Met: 23
Measure in red is a GPRAMA measure.

